KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Exact Sciences (EXAS) Total Current Liabilities (2016 - 2025)

Exact Sciences (EXAS) has disclosed Total Current Liabilities for 16 consecutive years, with $641.2 million as the latest value for Q4 2025.

  • On a quarterly basis, Total Current Liabilities fell 12.43% to $641.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $641.2 million, a 12.43% decrease, with the full-year FY2025 number at $641.2 million, down 12.43% from a year prior.
  • Total Current Liabilities was $641.2 million for Q4 2025 at Exact Sciences, up from $584.3 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $732.2 million in Q4 2024 to a low of $367.4 million in Q1 2023.
  • A 5-year average of $553.8 million and a median of $517.1 million in 2021 define the central range for Total Current Liabilities.
  • Peak YoY movement for Total Current Liabilities: skyrocketed 180.91% in 2021, then plummeted 40.35% in 2022.
  • Exact Sciences' Total Current Liabilities stood at $517.1 million in 2021, then fell by 20.18% to $412.7 million in 2022, then rose by 24.7% to $514.7 million in 2023, then surged by 42.25% to $732.2 million in 2024, then fell by 12.43% to $641.2 million in 2025.
  • Per Business Quant, the three most recent readings for EXAS's Total Current Liabilities are $641.2 million (Q4 2025), $584.3 million (Q3 2025), and $521.9 million (Q2 2025).